Eliyahou Et Al Harari executed the largest-ever insider purchase in CapsoVision history, buying 878,735 shares for $5M, signaling strong conviction in the company's AI-driven growth strategy. This significant capital commitment comes as the stock trades near its 52-week low, potentially offering a contrarian entry point.
Price context
CV is down 13.52% over the last 90 days and sits 21.44% below its 52-week high of $7.695, currently trading at $6.045. The stock has shown recent resilience with a 1.0% gain over the past 5 days.
Catalysts to watch
- •Q2 2026 earnings on August 14, 2026, where revenue grew 10% driven by the AI launch in the EU.
- •FDA 510(k) submission for the AI-assisted module in CapsoCam Plus on January 2, 2026.
- •Upcoming AI-driven roadmap for colon and pancreas screening outlined during the March 24, 2026 conference.
Risks
- •Margin compression and FDA delays noted in the Q2 2026 earnings highlights could impact profitability.
- •The stock is currently down 13.52% over the last 90 days, indicating significant recent selling pressure.
AI-generated context from public data. Not investment advice. Verify before trading.